Y Intercept Hong Kong Ltd Takes Position in DaVita Inc. (NYSE:DVA)

Y Intercept Hong Kong Ltd acquired a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,474 shares of the company's stock, valued at approximately $1,225,000.

A number of other large investors have also recently bought and sold shares of DVA. Transcendent Capital Group LLC acquired a new position in shares of DaVita during the 3rd quarter worth $25,000. Blue Trust Inc. grew its position in DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company's stock valued at $29,000 after acquiring an additional 78 shares during the last quarter. Family Firm Inc. acquired a new position in DaVita during the second quarter worth about $43,000. Quarry LP bought a new position in shares of DaVita in the third quarter worth about $60,000. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of DaVita in the 2nd quarter valued at approximately $68,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Trading Down 1.0 %

NYSE DVA traded down $1.60 on Thursday, hitting $153.90. The company's stock had a trading volume of 463,650 shares, compared to its average volume of 810,685. The firm has a market cap of $12.62 billion, a PE ratio of 16.77, a PEG ratio of 0.90 and a beta of 0.90. The company's 50-day moving average is $158.21 and its 200 day moving average is $150.66. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. DaVita Inc. has a 1-year low of $103.40 and a 1-year high of $169.51.

DaVita (NYSE:DVA - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm's quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.85 earnings per share. As a group, analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Activity at DaVita

In related news, CEO Javier Rodriguez sold 9,881 shares of the firm's stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the completion of the sale, the chief executive officer now owns 887,835 shares of the company's stock, valued at $144,583,929.75. This trade represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages recently commented on DVA. Barclays increased their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research note on Thursday, October 31st. Truist Financial increased their price target on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research note on Monday, October 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, DaVita has a consensus rating of "Hold" and a consensus target price of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.